<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759354</url>
  </required_header>
  <id_info>
    <org_study_id>V419-012</org_study_id>
    <secondary_id>2016-000274-37</secondary_id>
    <secondary_id>PRI03C</secondary_id>
    <nct_id>NCT02759354</nct_id>
  </id_info>
  <brief_title>Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With VAXELIS or INFANRIX Hexa</brief_title>
  <official_title>Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With a 2-dose or 3-dose Infants Series and Toddler Dose With VAXELIS or INFANRIX Hexa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MCM Vaccines B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe long-term persistence of Hepatitis B and pertussis antibody responses in healthy
      4- to 5 Year old children previously vaccinated with VAXELIS or INFANRIX hexa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Actual">August 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-hepatitis B surface antigen (HBs) concentration ≥ 10 mIU/mL</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with anti-pertussis toxin, anti-filamentous hemagglutinin, anti- pertactin, and anti-fimbriae concentrations ≥ the lower limit of quantification (LLOQ), ≥ 2x LLOQ, and ≥ 4x LLOQ</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Geometric Mean Concentration (GMC)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Pertussis Geometric Mean Concentration (GMC)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious Adverse Event related to study procedure</measure>
    <time_frame>Within 3-4 days following Blood Sample taken on Day 1</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Group V3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with a 3+1 schedule with VAXELIS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously vaccinated with a 3+1 schedule with Infanrix hexa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with a 2+1 schedule with VAXELIS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously vaccinated with a 2+1 schedule with Infanrix hexa</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>Blood sample at approx. 4 years of age</description>
    <arm_group_label>Group V3</arm_group_label>
    <arm_group_label>Group I3</arm_group_label>
    <arm_group_label>Group V2</arm_group_label>
    <arm_group_label>Group I2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Healthy child of either gender, who has received a complete 3-dose primary series or a
             complete 2 dose primary series followed by a toddler dose with VAXELIS or INFANRIX
             hexa as part of the V419-007 or V419-008 study respectively;

          2. Informed consent signed by the subject's parent(s) or legal representative.

        Exclusion Criteria:

          1. Subject who has received any dose of HB containing vaccine at any time other than
             study vaccine in V419-007 or V419-008 study;

          2. Subject with a history of diagnosis (clinical, serological or microbiological) of HB
             virus infection of the V419-007 or V419-008 study;

          3. Subject who has received any dose of pertussis containing vaccine after completion of
             the V419-008 study;

          4. Subject with a history of diagnosis (clinical, serological or microbiological) of
             infection due to pertussis after completion of V419-008 study;

          5. Participation at the time of study enrolment or in the 4 weeks preceding the study
             enrolment in another clinical study investigating a vaccine, drug medical device, or
             medical procedure;

          6. Subject who received immunoglobulins, blood or blood-derived products within 3 months
             prior to inclusion;

          7. Receipt of immunosuppressive therapy or other immune-modifying drugs, such as
             anti-cancer chemotherapy or radiation therapy since completion of V419-007 or V419-008
             studies;

          8. Subject with suspected or known blood dyscrasias, leukemia, lymphomas of any type or
             other malignant neoplasms affecting the haematopietic and lymphatic systems since
             completion of V419-007 or V419-008 studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0007</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0005</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0006</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0004</name>
      <address>
        <city>Jarvenpaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0010</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0008</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0003</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0009</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0001</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0002</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

